Industry
Biotechnology
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
March 27, 2024 | 1:22 pm
Portfolio Pulse from Benzinga Newsdesk
March 26, 2024 | 4:41 pm
Portfolio Pulse from Benzinga Newsdesk
March 26, 2024 | 11:08 am
Portfolio Pulse from Benzinga Insights
March 26, 2024 | 8:47 am
Portfolio Pulse from Benzinga Insights
March 25, 2024 | 4:05 pm
Portfolio Pulse from Benzinga Newsdesk
March 21, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
March 08, 2024 | 1:57 pm
Portfolio Pulse from Benzinga Newsdesk
March 08, 2024 | 1:52 pm
Portfolio Pulse from Benzinga Newsdesk
February 21, 2024 | 1:24 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.